112758-89-1

Basic information

• Product Name: tert-butyl2-(piperazin-1-yl)ethylcarbamate
• Synonyms: 1-Phenyl-1,2,3,4-Tetrahydropyr;1-phenyl-1,2,3,4-tetrahydropyrrolo[1,2-a]pyrazine(SALTDATA: FREE);1-phenyl-1H,2H,3H,4H-pyrrolo[1,2-a]pyrazine;1,2,3,4-Tetrahydro-1-phenylpyrrolo[1,2-a]pyrazine
• CAS NO: 112758-89-1
• Molecular Formula: C₁₃H₁₄N₂
• Molecular Weight: 229.31922
• Mol File: 112758-89-1.mol

Chemical Properties

• Melting Point: 73-74 °C
• Boiling Point: 343°C at 760 mmHg
• Flash Point: 161.2°C
• Appearance: /
• Density: 1.15g/cm³
• Vapor Pressure: 7.26E-05mmHg at 25°C
• Refractive Index: 1.638
• Storage Temp.: 2-8°C
• PKA: 6.65±0.40(Predicted)
• CAS DataBase Reference: tert-butyl2-(piperazin-1-yl)ethylcarbamate(CAS DataBase Reference)
• NIST Chemistry Reference: tert-butyl2-(piperazin-1-yl)ethylcarbamate(112758-89-1)
• EPA Substance Registry System: tert-butyl2-(piperazin-1-yl)ethylcarbamate(112758-89-1)

Safety Data

• HazardClass: IRRITANT
• Hazardous Substances Data: 112758-89-1(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
Tert-butyl2-(piperazin-1-yl)ethylcarbamate is used as a pharmaceutical intermediate for the synthesis of various drugs, including antihistamines and antimicrobial agents, due to its versatile pharmacological properties.
Used in Research and Development:
tert-butyl2-(piperazin-1-yl)ethylcarbamate is utilized as a research chemical, aiding in the discovery and development of new pharmaceuticals and understanding of biological processes.
Used in Organic Synthesis:
Tert-butyl2-(piperazin-1-yl)ethylcarbamate is employed as a building block in organic synthesis, contributing to the creation of complex organic molecules for various applications.

InChI:InChI=1/C13H14N2/c1-2-5-11(6-3-1)13-12-7-4-9-15(12)10-8-14-13/h1-7,9,13-14H,8,10H2

Upstream product

• 111609-55-3 1-phenyl-3,4-dihydropyrrolo<1,2-a>pyrazine 
• 108-86-1 bromobenzene 
• 71257-37-9 3,4-dihydropyrrolo[1,2-a]-pyrazine 
• 71257-38-0 1,2,3,4-Tetrahydropyrrolo<1,2-a>pyrazine 
• 29709-35-1 1-(2-aminoethyl)pyrrole 
• 100-52-7 benzaldehyde 
• 98-88-4 benzoyl chloride 
• 136927-87-2 1-(2-(N-benzoylamino)ethyl)pyrrole 

Downstream Products

• 155206-41-0 1-cyclohexyloctahydropyrrolo<1,2-a>pyrazine 
• 1020656-54-5 tert-butyl 2-oxo-2-(1-phenyl-3,4-dihydropyrrolo[1,2-a]pyrazin-2(1H)-yl)ethylcarbamate 
• 1020656-18-1 4-oxo-4-(1-phenyl-3,4-dihydropyrrolo[1,2-a]pyrazin-2(1H)-yl)butanoic acid 
• 1020656-67-0 3-oxo-3-(1-phenyl-3,4-dihydropyrrolo[1,2-a]pyrazin-2(1H)-yl)propanoic acid methyl ester 
• 1174283-09-0 N-(2-(2-(1-tert-butyl-3,4-dihydropyrrolo[1,2-a]pyrazin-2(1H)-yl)-2-oxoethoxy)ethyl)-N,2,4,6-tetramethylbenzenesulfonamide 
• 1174282-70-2 4-methoxy-N,2,3,6-tetramethyl-N-(2-(2-(1-methyl-3,4-dihydropyrrolo[1,2-a]pyrazin-2(1H)-yl)-2-oxoethoxy)ethyl)benzenesulfonamide 
• 1174283-11-4 N,2,4,6-tetramethyl-N-(2-(2-oxo-2-(1-(pyridin-3-yl)-3,4-dihydropyrrolo[1,2-a]pyrazin-2(1H)-yl)ethoxy)ethyl)benzenesulfonamide 
• 1174282-63-3 N-(2-(2-(5,6-dihydroimidazo[1,2-a]pyrazin-7(8H)-yl)-2-oxoethoxy)ethyl)-N-isobutyl-4-methoxy-2,3,6-trimethylbenzenesulfonamide 
• 1174282-88-2 N-benzyl-4-methoxy-2,6-dimethyl-N-(2-(2-(1-methyl-3,4-dihydropyrrolo[1,2-a]pyrazin-2(1H)-yl)-2-oxoethoxy)ethyl)benzenesulfonamide 
• 1174283-17-0 N-(2-(2-(1-(3-fluorophenyl)-3,4-dihydropyrrolo[1,2-a]pyrazin-2(1H)-yl)-2-oxoethoxy)ethyl)-N,2,4,6-tetramethylbenzenesulfonamide 
• 1174282-82-6 N-benzyl-4-methoxy-2,3,6-trimethyl-N-(2-(2-(1-methyl-3,4-dihydropyrrolo[1,2-a]pyrazin-2(1H)-yl)-2-oxoethoxy)ethyl)benzenesulfonamide 
• 1174283-06-7 4-methoxy-N-(2-(2-(1-(3-methoxyphenyl)-3,4-dihydropyrrolo[1,2-a]pyrazin-2(1H)-yl)-2-oxoethoxy)ethyl)-N,2,6-trimethylbenzenesulfonamide 
• 1174282-85-9 N-benzyl-N-(2-(2-(5,6-dihydroimidazo[1,2-a]pyrazin-7(8H)-yl)-2-oxoethoxy)ethyl)-4-methoxy-2,3,6-trimethylbenzenesulfonamide 
• 1174282-72-4 N-(2-(2-(1-(6-chloropyridin-3-yl)-3,4-dihydropyrrolo[1,2-a]pyrazin-2(1H)-yl)-2-oxoethoxy)ethyl)-4-methoxy-N,2,3,6-tetramethylbenzenesulfonamide 

Relevant articles and documents

A Robust, Recyclable Resin for Decagram Scale Resolution of (±)-Mefloquine and Other Chiral N-Heterocycles

Decagram quantities of enantiopure (+)-mefloquine have been produced via kinetic resolution of racemic mefloquine using a ROMP-gel supported chiral acyl hydroxamic acid resolving agent. The requisite monomer was prepared in a few synthetic steps without chromatography and polymerization was safely performed on a >30 gram scale under ambient conditions. The reagent was readily regenerated and reused multiple times for the resolution of 150 grams of (±)-mefloquine and other chiral N-heterocylces.

Substituted Sulfonamide Compounds

Substituted sulfonamide compounds corresponding to the formula I wherein m, n, p, Q, R1, R2, R3, R4, X, Y and Z have the respective meanings defined herein, pharmaceutical compositions containing such compounds, a process for their preparation, and the use of such compounds for the treatment and/or inhibition of pain and other conditions mediated by bradykinin receptor 1 (B1R) and/or bradykinin receptor 2 (B2R).

SUBSTITUTED SULFONAMIDE DERIVATIVES

The invention relates to substituted sulfonamide derivatives of the general formula (I'); processes for their preparation, medicaments containing these compounds, and the use of substituted sulfonamide derivatives for the preparation of medicaments

HETEROCYCLODIAZEPINE CANNABINOID RECEPTOR MODULATORS FOR TREATMENT OF DISEASE

The present invention relates to compounds and methods useful as modulators of CB2 for the treatment or prevention of disease states including, but not limited to pain, autoimmune disease, malabsorption syndrome, pulmonary disease, osteoporosis, muscle spasm in cancer, neuromuscular disorder, and atherosclerosis progression.

Substituted Tetrahydropyrrolopyrazine Compounds and the Use Thereof in the Treatment and/or Inhibition of Pain

Substituted tetrahydropyrrolopyrazine compounds corresponding to the formula I: processes for their preparation, pharmaceutical compositions comprising these compounds and the use of these compounds for the treatment and/or inhibition of pain and other disorders or disease states at least partly mediated by KCNQ2/3 K+ channels.